Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Aberdeen Group plc boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 51.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,469,951 shares of the biopharmaceutical company’s stock after acquiring an additional 496,295 shares during the quarter. Aberdeen Group plc owned 1.52% of Ultragenyx Pharmaceutical worth $33,809,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Covestor Ltd grew its holdings in shares of Ultragenyx Pharmaceutical by 26.0% during the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 369 shares in the last quarter. Huntington National Bank boosted its position in Ultragenyx Pharmaceutical by 56.2% during the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Xponance Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 3.1% during the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 406 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 2.3% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock valued at $690,000 after purchasing an additional 434 shares during the last quarter. Finally, Amalgamated Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 6.9% in the third quarter. Amalgamated Bank now owns 7,226 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 469 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on RARE shares. The Goldman Sachs Group cut shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Wedbush reissued a “neutral” rating and set a $25.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. Bank of America reduced their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Robert W. Baird decreased their price objective on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Finally, Leerink Partners lowered their target price on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $60.47.

Ultragenyx Pharmaceutical Price Performance

RARE opened at $22.45 on Friday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.29 and a 12-month high of $42.37. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -3.84 and a beta of 0.25. The business has a 50 day moving average of $22.20 and a 200-day moving average of $27.75.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same period in the previous year, the firm posted ($1.39) earnings per share. The firm’s revenue was up 25.5% compared to the same quarter last year. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 54,404 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the transaction, the chief executive officer directly owned 658,994 shares of the company’s stock, valued at $15,025,063.20. This represents a 7.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John Richard Pinion sold 10,029 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $228,661.20. Following the sale, the insider owned 110,026 shares of the company’s stock, valued at approximately $2,508,592.80. This represents a 8.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 109,556 shares of company stock valued at $2,490,138. Corporate insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FDA accepts the BLA resubmission for UX111 (AAV gene therapy for Sanfilippo syndrome type A). Acceptance starts a formal FDA review clock and materially improves near‑term clarity on a high‑value gene‑therapy program, which can lift pipeline valuation and upside expectations if the review proceeds smoothly. Read More.
• Neutral Sentiment: CFO Howard Horn disclosed sale of 4,683 shares under a pre‑arranged Rule 10b5‑1 plan; he retains a large position. Because the sale was executed under a 10b5‑1 schedule and his holding remains substantial, markets typically treat this as routine liquidity rather than a signal of undisclosed company problems. Read More.
• Neutral Sentiment: Recent analyst target/coverage updates (mix of cuts and reiterations) keep consensus near a “Moderate Buy” but with wide dispersion in targets, leaving valuation opinion split among investors. (Coverage changes may moderate momentum but are not a single catalytic change.)
• Negative Sentiment: Multiple plaintiff law firms have issued lead‑plaintiff solicitations for a securities class action covering Aug 3, 2023–Dec 26, 2025, with an imminent April 6 deadline. The wave of notices signals an active litigation overhang that can pressure the stock via potential discovery, legal costs, management distraction and settlement risk until the matter is resolved or clarified. Representative notices: Rosen Law Firm and Berger Montague. Read More. Read More.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.